Pharmerging Market To Experience Lucrative Growth Due To Growing Chronic Diseases Till 2024: Grand View Research, Inc.

The global pharmerging market is expected to reach USD 2,231.9 billion by 2025, according to a new report by Grand View Research, Inc. This market is expected to grow due to increasing geriatric population, increasing disease burden of chronic disorders and increasing healthcare expenditure. 

According to the United Nations (UN), the number of people above the age of 60 years are estimated to be 901 million in 2015. This number is expected to increase to 1.4 billion by 2030 and 2.1 billion by 2050. The increasing geriatric population boosts the demand for better treatment options for chronic diseases such as hyperlipidemia, hypertension, cancer, dementia, congestive heart failure. According to a study conducted by Deloitte in 2011, the geriatric population accounts for almost 23.0-40.0% of the prescription drug market, and 40.0-50.0% of the OTC drug market.



Another driving factor for the pharmerging market is increasing healthcare expenditure. The global healthcare spending is expected to increase from USD 7.83 trillion in 2013 to USD 18.28 trillion in 2040. It has also been estimated that there will an increase of 3.4%, 3.0%, 2.4% in healthcare expenditure in upper middle-level income countries, lower middle-level income countries and in low-income level countries respectively.

The increasing disease burden of chronic diseases in developing countries is boosting the growth in the market. According to the Global Health Observatory data, in 2015, 70.0% of the deaths were due to non-communicable diseases (NCD). The major NCDs are cardiovascular diseases (CVD) which caused 45.0% of all NCD deaths, cancer which caused 22.0% of all NCD deaths and chronic obstructive pulmonary disease (COPD) which causes 10.0% of all NCD deaths, and diabetes which caused 4.0% of all NCD deaths.

Browse full research report on Pharmerging Market: www.grandviewresearch.com/industry-analysis/pharmerging-market 
                                                                                
Further key findings from the report suggest:

  • Pharmaceutical segment was the major contributor for the pharmerging market in 2016.
  • Pharmaceutical sector also recorded the fastest growth in the pharmerging industry.
  • Tier I is driving growth in the pharmerging market.
  • India among the Tier II countries is estimated to witness the fastest growth in the pharmerging industry.
  • Brazil was recorded as the major contributor for Tier II countries.
  • Among Tier III countries, Nigeria and Indonesia are estimated to be driving growth.
  • The key players include Sanofi, Pfizer Inc., AstraZeneca, GlaxoSmithKline, F.Hoffmann-La Roche, GE Healthcare, Eli Lilly, Medtronic, Johnson and Johnson, Abbott.
  • The key strategic initiatives include new product launches, acquisitions and mergers, and collaborations.
Browse more reports of this category by Grand View Research: www.grandviewresearch.com/industry/healthcare                                                                                
Grand View Research has segmented the pharmerging market by product, and region:

Pharmerging Regional Outlook (Revenue, USD Billion; 2014 - 2025)
  • Tier I
    • China
  • Tier II
    • India
    • Brazil
    • Russia
    • South Africa
  • Tier III
    • Argentina
    • Mexico
    • Poland
    • Ukraine
    • Turkey
    • Saudi Arabia
    • Egypt
    • Algeria
    • Nigeria
    • Thailand
    • Indonesia
    • Pakistan
    • Saudi Arabia
Pharmerging Product Outlook (Revenue, USD Billion; 2014 - 2025)
  • Pharmaceutical
    • Patented prescription drugs
    • Generic prescription drug
    • OTC drugs
  • Other healthcare verticals
    • Medical device
    • Clinical diagnostics
    • Other

Access Press Release By Grand View Research: www.grandviewresearch.com/press-release/global-pharmerging-market    
                                  
About Grand View Research:

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


For more information: www.grandviewresearch.com

Comments

Post a Comment

Popular posts from this blog

Epigenetics Market to Observe Strong Development by 2022

The global  epigenetics market  is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.  Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is expected to attract pharmaceutical companies to collaborate for the development of therapeutic drugs.  Presence of pipeline drugs and their expected commercialization is anticipated to boost penetration rates over the forecast period. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.  Technology advancements in the field of epigenetics especially pertaining to t
Read more

Increasing Incidences Of M&A Of CDMO/CRO With Big Pharma Companies To Drive Life Sciences BPO Market Growth Till 2024: Grand View Research, Inc.

Image
The  life sciences BPO market  is expected to reach USD 420 billion by 2024, according to a new report by Grand View Research, Inc. The lucrative growth is attributed to the growing demand for contract manufacturing of raw materials, Finished Dosage Forms (FDFs), medical devices, drug discovery services, regulatory services, pre-clinical and clinical trial services, and pharmacovigilance services.  The pharmaceutical and biotech industry invests heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of the drug development such as drug discovery, pre-clinical studies, and clinical trials require huge financial, technological, and human resources.  North America life sciences BPO market, by services, 2013 - 2024 (USD Billion) In order to cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth
Read more

U.S. Telehealth Market Is To Be $2.83 Billion By 2022: Grand View Research, Inc.

Image
U.S. telehealth market  is expected to reach USD 2.8 billion by 2022, according to a new report by Grand View Research Inc. Increasing access to basic healthcare is the major aim of telehealth along with improved healthcare quality and patient safety by early detection and diagnosis. According to a report published by the Agency for Health Care Research and Quality (AHRQ), implementation of telehealth solution improves quality of care delivery to patients.  The rising demand for self care and independent living along with the concept of home care is highly appealing to the population. The Rhode Island Partnership for Home Care reported that in 2014, over 20,000 citizens demanded for home care that led to approximately 1,000,000 visits by healthcare providers. Advantages that drive the higher adoption for home care include better psychological impact on patients, provision of friendly environment, care provision as per patient needs, and cost-effectiveness.  U.S. telehealth
Read more